Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 13/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22914751 | 0.83 | LMNA (0.64) | LMNASLC6A9SLC6A5KCNH2ALDH1A1 | |
| SCHEMBL22914750 | 0.78 | CYP2D6 (0.50) | CYP1A2TSHRCYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL22914756 | 0.77 | ENPP2 (0.45) | LMNATSHRALDH1A1 | |
| SCHEMBL22919227 | 0.74 | AR (0.44) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL4147771 | 0.73 | SLC6A9 (0.56) | LMNASLC6A9SLC6A5KCNH2ALDH1A1 | |
| SCHEMBL22914839 | 0.71 | CYP3A4 (0.55) | CYP1A2TSHRKCNH2CYP2D6CYP3A4 | |
| SCHEMBL355131 | 0.70 | GPR119 (0.68) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL29378266 | 0.70 | GPR119 (0.68) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL251355 | 0.70 | SLC6A9 (0.45) | LMNASLC6A9SLC6A5KCNH2OPRM1 | |
| SCHEMBL248276 | 0.69 | LMNA (0.52) | LMNASLC6A9SLC6A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024492-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | LMNA 1587/4885SLC6A9 4834/4885SLC6A5 4156/4885 |
| US-20210024495-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | LMNA 1587/4885SLC6A9 4834/4885SLC6A5 4156/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | LMNA 1587/4885SLC6A9 4834/4885SLC6A5 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.